Cenobamate Precision Management in Drug-Resistant Epilepsy: A Five-Patient Case Series

Five detailed patient cases illustrate the integration of pharmacogenetics and therapeutic drug monitoring for cenobamate in drug-resistant epilepsy. The data originates from an exploratory case series by Giuseppe d’Orsi, selected from a cohort of 125 individuals, and was last updated in June 2026. It describes clinical outcomes, metabolizer phenotypes, and personalized dosing strategies.

Use Cases

• Study the relationship between UGT2B7/CYP2E1 genotypes and cenobamate response based on pharmacogenetic profiling.
• Analyze dose-limiting toxicity scenarios involving drug-drug-gene interactions based on described CYP2C19 inhibition cases.
• Evaluate personalized titration strategies for minimizing polypharmacy based on the sub-target dose protocol described.
• Investigate the correlation between predicted 'Ultrarapid Metabolizer' phenotypes and non-response based on the case series observations.

Strengths

• Includes detailed clinical, therapeutic drug monitoring, and pharmacogenetic data for five patients.
• Integrates targeted Next-Generation Sequencing results for seven key metabolic genes.
• Published under a permissive CC-BY-4.0 license for reuse.

Limitations

• Description metadata is limited; actual data quality requires manual inspection after download.
• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.

Provenance

Source

Giuseppe d’Orsi via figshare

Collection Method

Exploratory case series selected from a cohort of 125 patients.

Freshness

Last updated 2026-06-04 05:40:01; freshness should be verified.